Show simple item record

dc.contributor.authorSerrano Lopez, Dolores Remedios
dc.contributor.authorLalatsa, Aikaterini
dc.date.accessioned2013-11-13T12:01:10Z
dc.date.available2013-11-13T12:01:10Z
dc.date.issued2013-04
dc.identifier.citationSerrano Lopez , D R & Lalatsa , A 2013 , ' Peptide pills for brain diseases? Reality and future perspectives ' , Therapeutic Delivery , vol. 4 , no. 4 , pp. 479-501 . https://doi.org/10.4155/tde.13.5
dc.identifier.issn2041-5990
dc.identifier.otherPURE: 2092976
dc.identifier.otherPURE UUID: 189370ef-044d-48a8-a57d-aa5b5baf238b
dc.identifier.otherPubMed: 23557289
dc.identifier.otherScopus: 84875957167
dc.identifier.urihttp://hdl.handle.net/2299/12119
dc.description.abstractThe peptide therapeutic market is one of the fastest growth areas of the pharmaceutical industry. Although few orally administered peptides are marketed and many are in different phases of clinical development, there is no marketed oral peptide therapeutic used for CNS disorders. The major challenges involved in orally delivering peptides to the brain relate to their enzymatic instability and inability to permeate across physiological barriers. The paucity of therapies for the treatment of brain diseases and the presence of the blood-brain barrier excluding 98% of therapeutic molecules necessitates parenteral administration. Various approaches have been applied to enhance oral peptide bioavailability, but only nanoparticulate strategies were able to deliver orally therapeutic peptides to the brain. Although industry may be reluctant to invest in developing oral peptide nanomedicines, the increasingly unmet clinical need and economic burden associated with brain diseases will fuel the development of the first marketed oral-to-brain peptide therapy.en
dc.format.extent23
dc.language.isoeng
dc.relation.ispartofTherapeutic Delivery
dc.subjectAdministration, Oral
dc.subjectAnimals
dc.subjectDrug Stability
dc.subjectNanomedicine
dc.subjectProtein Stability
dc.subjectHumans
dc.subjectCapillary Permeability
dc.subjectBrain Diseases
dc.subjectDrug Design
dc.subjectBiological Availability
dc.subjectBiotransformation
dc.subjectPeptides
dc.subjectCentral Nervous System Agents
dc.subjectBlood-Brain Barrier
dc.titlePeptide pills for brain diseases? : Reality and future perspectivesen
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionNanopharmaceutics
dc.contributor.institutionPharmaceutics
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
dcterms.dateAccepted2013-04
rioxxterms.versionofrecordhttps://doi.org/10.4155/tde.13.5
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record